EUR 13.36 For Business Accounts Only

With a more favourable environment, SEIKAGAKU CORP. improves to Slightly Positive

SEIKAGAKU CORP. (JP), a company active in the Pharmaceuticals industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 3 out of 4 stars, as well as its unchanged, moderately risky market behaviour. The title leverages a more favourable environment and raises its general evaluation to Slightly Positive. As of the analysis date September 19, 2017, the closing price was JPY 1,959.00 and its potential was estimated at JPY 2,143.51.
Seikagaku Corp.

Seikagaku and its subsidiaries are mainly engaged in the research and development, manufacture, purchase and sale of medical devices specifically related to glycoconjugates. Co. operates in two business segments. Pharmaceutical segment offers pharmaceutical products made from hyaluronic acid, a major component of glycoconjugates including joint function improving agents, ophthalmic surgical aids, surgical aids for endoscopic mucosal resection, and bulk products. Limulus amebocyte lysate ("LAL") segment offers endotoxin-detecting reagents made from LAL and other, to be used for quality control in the manufacturing process of pharmaceuticals and release test and medical devices.


Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded


Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch